Lars Erik Kristensen (Former)
1 – 20 of 56
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Response to : Response to: Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: Is it an overlooked comorbidity?' by Proft et al.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis
(
- Contribution to journal › Article
-
Mark
Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity : 52-Week Post Hoc Results from SPIRIT-H2H
(
- Contribution to journal › Article
-
Mark
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
(
- Contribution to journal › Article
- 2021
-
Mark
Chronic Pain and Assessment of Pain Sensitivity in Patients With Axial Spondyloarthritis : Results From the SPARTAKUS Cohort
(
- Contribution to journal › Article
- 2020
-
Mark
Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls : Is it an overlooked comorbidity?
(
- Contribution to journal › Letter
-
Mark
The implications of an aging population and increased obesity for knee arthroplasty rates in Sweden : a register-based study
(
- Contribution to journal › Article
- 2019
-
Mark
Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis : Results from the SPARTAKUS cohort
(
- Contribution to journal › Article
- 2018
-
Mark
Patient-Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologics-Treated Patients With Rheumatoid Arthritis
(
- Contribution to journal › Article
-
Mark
Protocol for evaluating and implementing a pragmatic value-based healthcare management model for patients with inflammatory arthritis : A Danish population-based regional cohort and qualitative implementation study
(
- Contribution to journal › Article
-
Mark
Non-pharmacological Effects in Switching Medication : The Nocebo Effect in Switching from Originator to Biosimilar Agent
(
- Contribution to journal › Article
-
Mark
Burden of rheumatoid arthritis in the Nordic region, 1990-2015 : a comparative analysis using the Global Burden of Disease Study 2015
(
- Contribution to journal › Article
- 2017
-
Mark
Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
(
- Contribution to journal › Article
-
Mark
EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy : A prospective observational study of patients registered in the south Swedish SSATG registry
(
- Contribution to journal › Article
-
Mark
Work disability in newly diagnosed patients with primary sjögren syndrome
(
- Contribution to journal › Article
-
Mark
Cancer risk in patients with spondyloarthritis treated with TNF inhibitors : A collaborative study from the ARTIS and DANBIO registers
(
- Contribution to journal › Article
-
Mark
Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy : A population-based regional cohort study from southern Sweden
(
- Contribution to journal › Article
- 2016
-
Mark
Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.
(
- Contribution to journal › Article
-
Mark
Mortality in ankylosing spondylitis: results from a nationwide population-based study.
(
- Contribution to journal › Article
-
Mark
Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis : Observational Data from Southern Sweden
(
- Contribution to journal › Article